Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ARDX with free AI briefings, catalyst countdowns, and dilution alerts.

ARDX · ARDELYX, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$285.3M Cash on Hand
404.9mo Cash Runway
Follow ARDX by email Get an email when ARDX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ARDX, unsubscribe in one click. Privacy

📣 What ARDX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tenapanor
FDA approved Sep 2019 · Ibsrela
IBS Phase 4 · NCT05995899 Completed
RDX5791 Constipation Predominant Irritable Bowel Syndrome Phase 2 · NCT01340053 Completed
RDX227675 Hyperkalemia Phase 2 · NCT03018067 Terminated
RDX013 Hyperkalemia Phase 2 · NCT04780841 Completed
AZD1722 salt tablet Healthy Volunteers Food Interaction Study Phase 1 · NCT02226783 Completed
AZD1722 free base tablet Healthy Volunteers Food Interaction Study Phase 1 · NCT02226783 Completed
Treatment A (rosuvastatin) Healthy Volunteers Phase 1 · NCT02140281 Completed
Treatment B - AZD1722 followed by cefadroxil Healthy Volunteers Phase 1 · NCT02140281 Completed

Also used in these trials (approved or third-party drugs, not ARDX's own candidates): Sevelamer Carbonate, Omeprazole, Midazolam Hydrochloride.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ARDX holds $285.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.1M/quarter from operations, an estimated runway of 404.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ARDX files for a raise →

👥 Who Owns ARDX

Insiders 3.5% Other 5%+ holders 5.6% Institutions (322 holders) 73.1% Public and other holders 17.8%
HolderTypeShares% of sharesAs of
Rubric Capital Management LP Institution (13G, 5%+) 16,202,700 6.45% 2026-06-30
Millennium Management LLC 5%+ holder (13G) 14,200,773 5.65% 2026-06-30
STATE STREET CORPORATION Institution (13G, 5%+) 13,604,307 5.41% 2026-03-31
David M Mott
Director · +39,715 options
Insider 3,349,655 1.33% 2026-06-16
Michael Raab
President & CEO, Director · +290,834 options
Insider 1,620,792 0.64% 2026-08-21
Richard J Rodgers
Director · +39,715 options
Insider 439,998 0.18% 2026-06-16
Eric Duane Foster
Chief Commercial Officer
Insider 409,410 0.16% 2026-08-21
Laura A Williams
Chief Patient Officer · +31,000 options
Insider 367,456 0.15% 2026-08-21
Mike Kelliher
Chief Business Officer
Insider 349,660 0.14% 2026-08-21
William C JR Bertrand
Director · +39,715 options
Insider 329,507 0.13% 2026-06-16
John E Bishop
Chief Technical and Quality Officer
Insider 317,095 0.13% 2026-08-21
James Parker Brady
Chief Human Resources Officer
Insider 245,930 0.10% 2026-08-21

Share count 251,372,553 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ARDX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARDX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.